<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04155918</url>
  </required_header>
  <id_info>
    <org_study_id>AR882-201</org_study_id>
    <nct_id>NCT04155918</nct_id>
  </id_info>
  <brief_title>Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients</brief_title>
  <official_title>A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of AR882 Administered Alone or in Combination With Febuxostat or Allopurinol in Gout Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arthrosi Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arthrosi Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to evaluate the PK/PD, safety and tolerability of AR882 alone or in
      combination with febuxostat or allopurinol when administered to gout patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PD profile of AR882 administered alone or in combination with febuxostat</measure>
    <time_frame>22 Days</time_frame>
    <description>Profile from serum uric acid concentration over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PD profile of AR882 administered alone or in combination with allopurinol</measure>
    <time_frame>22 Days</time_frame>
    <description>Profile from serum uric acid concentration over time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum uric acid (sUA) response rate</measure>
    <time_frame>22 Days</time_frame>
    <description>sUA response rate to achieve sUA &lt;6, &lt;5, &lt;4, and &lt;3 mg/dL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) for plasma AR882</measure>
    <time_frame>22 Days</time_frame>
    <description>Profile from plasma in terms of AUC for AR882</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (Tmax) for AR882</measure>
    <time_frame>22 Days</time_frame>
    <description>Profile from plasma in terms of Tmax for AR882</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) for AR882</measure>
    <time_frame>22 Days</time_frame>
    <description>Profile from plasma in terms of Cmax for AR882</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life (t1/2) for AR882</measure>
    <time_frame>22 Days</time_frame>
    <description>Profile from plasma in terms of t1/2 for AR882</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount excreted (Ae) into urine for AR882</measure>
    <time_frame>22 Days</time_frame>
    <description>Profile from urine in terms of Ae for AR882</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance (CLr) for AR882</measure>
    <time_frame>22 Days</time_frame>
    <description>Profile from urine in terms of CLr for AR882</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC for plasma for febuxostat</measure>
    <time_frame>22 Days</time_frame>
    <description>Profile from plasma in terms of AUC for febuxostat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for febuxostat</measure>
    <time_frame>22 Days</time_frame>
    <description>Profile from plasma in terms of Tmax for febuxostat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for febuxostat</measure>
    <time_frame>22 Days</time_frame>
    <description>Profile from plasma in terms of Cmax for febuxostat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 for febuxostat</measure>
    <time_frame>22 Days</time_frame>
    <description>Profile from plasma in terms of t1/2 for febuxostat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC for plasma allopurinol/oxypurinol</measure>
    <time_frame>22 Days</time_frame>
    <description>Profile from plasma in terms of AUC for allopurinol/oxypurinol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for allopurinol/oxypurinol</measure>
    <time_frame>22 Days</time_frame>
    <description>Profile from plasma in terms of Tmax for allopurinol/oxypurinol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for allopurinol/oxypurinol</measure>
    <time_frame>22 Days</time_frame>
    <description>Profile from plasma in terms of Cmax for allopurinol/oxypurinol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 for for allopurinol/oxypurinol</measure>
    <time_frame>22 Days</time_frame>
    <description>Profile from plasma in terms of t1/2 for allopurinol/oxypurinol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae in urine for allopurinol/oxypurinol</measure>
    <time_frame>22 Days</time_frame>
    <description>Profile from urine in terms of Ae for allopurinol/oxypurinol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLr for allopurinol/oxypurinol</measure>
    <time_frame>22 Days</time_frame>
    <description>Profile from urine in terms of CLr for allopurinol/oxypurinol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC for plasma for colchicine</measure>
    <time_frame>22 Days</time_frame>
    <description>Profile from plasma in terms of AUC for colchicine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for colchicine</measure>
    <time_frame>22 Days</time_frame>
    <description>Profile from plasma in terms of Tmax for colchicine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for colchicine</measure>
    <time_frame>22 Days</time_frame>
    <description>Profile from plasma in terms of Cmax for colchicine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 for for colchicine</measure>
    <time_frame>22 Days</time_frame>
    <description>Profile from plasma in terms of t1/2 for colchicine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events, changes in laboratory, electrocardiogram, and vital signs</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>AR882/FBX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AR882/ALLO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 1: AR882 Alone and in Combination with Febuxostat (FBX)</intervention_name>
    <description>AR882 + Febuxostat, AR882 alone, Febuxostat alone</description>
    <arm_group_label>AR882/FBX</arm_group_label>
    <other_name>Febuxostat (Adenuric®, Uloric®)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 2: AR882 Alone and in Combination with Allopurinol (ALLO)</intervention_name>
    <description>AR882 + Allopurinol, AR882 alone, Allopurinol alone</description>
    <arm_group_label>AR882/ALLO</arm_group_label>
    <other_name>Allopurinol (Allosig®, Progout®, Zyloprim®)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  History of gout

          -  sUA &gt; 7 mg/dL

          -  Estimated Glomerular Filtration Rate (eGFR) ≥ 60 mL/min/1.73m2

        Key Exclusion Criteria:

          -  Malignancy within 5 years, except for successfully treated basal or squamous cell
             carcinoma of the skin

          -  History of cardiac abnormalities

          -  Active peptic ulcer disease or active liver disease

          -  History of kidney stones

          -  Allergy or intolerance to colchicine, febuxostat, and allopurinol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Wynne, MBChB, Grad Dip Pharm Med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Christchurch Clinical Studies Trust Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Director, Clinical Operations</last_name>
    <phone>+1 313-509-8611</phone>
    <email>info@arthrosi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Christchurch Clinical Studies Trust, Ltd (CCST)</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CCST Recruitment</last_name>
      <phone>+64 03 372 9477</phone>
      <phone_ext>706</phone_ext>
      <email>james@ccst.co.nz</email>
    </contact>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 25, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperuricemia</keyword>
  <keyword>Gout</keyword>
  <keyword>URAT1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

